Business Context and Reporting Period
This Form 8-K filing by Amphastar Pharmaceuticals, Inc. (Nasdaq: AMPH) reports a corporate governance event dated July 18, 2025. The Company is incorporated in Delaware and maintains its principal executive offices in Rancho Cucamonga, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board composition and director compensation.
Material Changes
- Board Expansion: The Board of Directors increased the authorized number of directors from ten (10) to eleven (11).
- New Appointment: David Gaugh was appointed as a Class I director, effective immediately, serving until the 2026 annual meeting of stockholders.
- Independence: The Board determined Mr. Gaugh is independent under Nasdaq listing standards.
Guidance, Outlook, and Compensation
There is no financial guidance, outlook, or discussion of risks and contingencies in this filing. Regarding compensatory arrangements for the new director:
- Initial Grant: Mr. Gaugh received an initial grant with an aggregate grant date fair value of $260,000.
- Composition: The grant consists of 50% restricted stock units and 50% stock options.
- Vesting: The award vests on the first anniversary of the grant date, subject to continued service.
- Future Compensation: Subsequent compensation will align with the Company's standard non-employee director compensation policy.
Investor Verification Checklist
- Verify the independence status of David Gaugh against Nasdaq listing standards.
- Review the Company's Proxy Statement on Schedule 14A (filed April 14, 2025) for details on the standard non-employee director compensation policy.
- Confirm the vesting schedule and performance conditions (if any) for the $260,000 initial grant.
- Check for any subsequent filings regarding Mr. Gaugh's committee assignments.